Human Tissue in the Evaluation of Safety and Efficacy of New Medicines: A Viable Alternative to Animal Models? by Coleman, Robert A.
International Scholarly Research Network
ISRN Pharmaceutics
Volume 2011, Article ID 806789, 8 pages
doi:10.5402/2011/806789
Review Article
Human Tissue in the Evaluation of Safety and Efﬁcacy of New
Medicines:A ViableAlternative to AnimalModels?
Robert A. Coleman
27 Wodehouse Terrace, Falmouth, Cornwall TR11 3EN, UK
Correspondence should be addressed to Robert A. Coleman, robt.coleman@btinternet.com
Received 18 April 2011; Accepted 15 May 2011
Academic Editors: K. Arimori and J. Arnold
Copyright © 2011 Robert A. Coleman.Thisisanopenaccessarticle distributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thepharma Industry’sability to develop safeand eﬀective new drugs tomarket is inseriousdecline. Arguably,a major contributor
to this is the Industry’s extensive reliance on nonhuman biology-based test methods to determine potential safety and eﬃcacy,
objective analysis of which reveals poor predictive value. An obvious alternative approach is to use human-based tests, but only if
they are available, practical, and eﬀective. While in vivo (phase 0 microdosing with high sensitivity mass spectroscopy) and in silico
(using established human biological data), technologies are increasingly being used, in vitro human approaches are more rarely
employed. However, not only are increasingly sophisticated in vitro test methods now available or under development, but the
basic ethically approved infrastructure through which human cells and tissues may be acquired is established. Along with clinical
microdosing and in silico approaches, more eﬀective access to and use of human cells and tissues in vitro provide exciting and
potentially more eﬀective opportunities for the assessment of safety and eﬃcacy of new medicines.
1.Introduction
It is generally agreed that the pharma industry has a problem
in bringing safe and eﬀective new drugs to market. This
may well be due, at least in part, to the overreliance of the
industry on using animals as human surrogates, an issue
that has been of concern to many working in the area
for decades [1–6]. Indeed, the most widely used animal
species, rodents, dogs, and even nonhuman primates, have
all been shown to be unreliable in their ability to predict
drug behaviour in man. A comparison of the bioavailability
of a range of drugs in man with that in these three species
by Grass and Sinko demonstrated a very poor level of
correlation [7]. Furthermore, the retrospective study by
Olson and colleagues [6] showed that for some systems,
the predictive value of animal studies to identify potential
toxicity in human subjects performed little better than the
spin of a coin. Interestingly, Olson’s ﬁndings correlate rather
well with those of Fletcher [3], published more than 20
years earlier. Further support has been generated in a study
on species concordance for liver injury [8]u s i n gas a f e t y
intelligence programme drawing on data in Medline and
EMEA European Public Assessment Reports (EPAR). In a
range of more than 800 (Medline) and 130 (EPAR) marketed
and withdrawn compounds with evidence of liver toxicity in
man, only 60% (Medline) and 49% (EPAR) proved similarly
toxic in rodents, and only 17% and 35% in both rodent
and nonrodent experimental species (Figure 1). In the light
of such questionable predictive power, it seems surprising
that such store is still set by animal safety data. While this
has always been the case, concern has been expressed that
animal shortcomings are set to become ever greater with the
increased focus on human-targeted biologicals [9]. There is
a strong case, therefore, to look more critically at the current
methods used to indicate the potential safety and eﬃcacy of
new drugs and to explore whether there are better ways of
doing it.
2.The Role of Animalsin
SafetyandEfﬁcacy Testing
It appears still to be widely believed that despite their
acknowledged shortcomings, animal studies are pivotal in
drug discovery, and it has been stated that “virtually every
medical achievement of the last century has depended2 ISRN Pharmaceutics
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Figure 1: Venn diagrams of compounds causing adverse eﬀects in the livers of humans, rodents, and/or nonrodents. (a) The numbers of
compounds causing eﬀects in each species class alone and in more than one class, and (b) the proportions of compounds reporting liver
eﬀects in humans that have eﬀects only in humans, in humans and rodents, in humans and nonrodents, and in all three species classes, as
deﬁned by assertions derived from Medline in a total of 1061 compounds (see http://www.biowisdom.com/downloads/SIP Board Species
Concordance.pdf).
directly or indirectly on research with animals” [10–12].
While a powerful statement, it is one that has spurious justi-
ﬁcation. In support, as far as new medicines are concerned,
it is undeniable that they will all have been tested in animals
and that these tests will have declared the compounds both
suﬃciently safe and eﬀective for evaluation in man. This is
so because the industry requires that drugs are demonstrably
eﬀective in their animal models before they will advance
thosedrugstotheclinicalstage.Andastosafety,asuﬃciently
blemish-free proﬁle in experimental animals is a mandatory
aspect of the regulatory approval process. So, while it is
true that all drugs have been tested and judged safe and
eﬀective in animals, it is not clear to what degree this is
relevant to their proﬁles in human subjects. Indeed, if it were
decreed that only compounds coloured yellow or smelling
of roses could advance to clinical testing, then all successful
drugs would have these characteristics, but it would be
absurd to suggest that these properties were essential to the
identiﬁcation of safe and eﬀective new medicines. What the
current conﬁdence in animal prediction ignores is ﬁrstly the
fact that the large majority of drugs entering clinical trials
are found either to lack clinical eﬃcacy or to cause either
u n d e s i r a b l es i d ee ﬀects or frank toxicity and secondly that
we have no idea how many potentially valuable medicines
have been committed to the dustbin on the basis of spurious
animal data.
To put the role of animal surrogates for human safety in
perspective,itisinterestingtoconsiderwhatwouldhappenif
safety in experimental animals was required for the approval
of foodstuﬀs for human consumption. If this was the case,
we would not have avocados, blue cheese, Brussels sprouts,
cabbage, chocolate, coﬀee, garlic, grapes, liquorice, onions,
or many other common and demonstrably safe foodstuﬀs
[13, 14], as all have proved to be poorly tolerated or even
toxic in rodents and/or dogs. And more to the point, the
recent experience with the Te Genero drug, TGN1412 [15]
that caused such devastating eﬀects in human volunteers at a
dose 500-fold lower than that well-tolerated by nonhuman
primates, illustrates the shortcomings of safety assessment
in animals, particularly in the case of agents speciﬁcally
designed to interact with human targets, as are an increasing
number of new biological medicines.
The situation is no better as far as predictions of eﬃcacy
are concerned. Cancer is a particularly good example, where
mouse models abound but have a very poor record in
predicting eﬃcacy in man [16–19]. It has been generally
accepted that approximately 95% of novel cancer drugs,
eﬀective in animal models, have proved to be ineﬀective
in the clinic [20, 21]. And if one looks at the current
armouryofantiasthmatreatments,primarilycorticosteroids,
beta-agonists, theophylline, cromones, and antileukotrienes,
only the latter can claim that the original discovery and
development of the class was based on animal experiments.
Conversely, if we review compounds promoted as potential
new treatments for asthma based on studies in mice, guinea
pigs, and sheep, we see, among others, antihistamines,
antagonists at neurokinin, bradykinin, PAF, thromboxane
and endothelin receptors, calcium channel blocking drugs,
potassium channel openers, statins, and PPAR gamma
agonists, none of which has ultimately proven clinically
useful [22–24].
The standing of the mouse as an experimental human
surrogate rose considerably with the completion of the
mouse and human genomes and the realisation of the fun-
damental genomic similarity of the two species. According
to Home Oﬃce statistics in 2008 in the UK, more than 2
million mice were used in scheduled procedures, and this
represented over 60% of the total number of animals used
[25]. A study of gene expression in mouse and man reveals
many critical diﬀerences: to take a speciﬁc example, it has
beendemonstratedthatthepatternsofbody-wideexpression
of 5-HT2b receptor mRNA in the two species are quite
diﬀerent [26]( Figure 2). Furthermore, there is only an 82%
concordance in the sequences of the genes encoding this
receptor in these two species [27]. And what is even more
important,astudyoftheaﬃnityofthisreceptortoitsnatural
ligand, 5-HT, revealed that the avidity of the mouse receptor
for 5-HT is at least 100-fold lower than that of the humanISRN Pharmaceutics 3
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Figure 2: Comparisonof QRT-PCRexpressionpatterns for 5-HT2B
in 20 tissues from mouse (red) and human (blue). Each numbered
radial arm represents a diﬀerent tissue type, and concentric circles
represent magnitude of gene expression in mRNA copy number per
100ng total RNA. Data points are mean values from 3 independent
values (i.e., generated from 3 samples of each tissue type, each
obtained from a separate animal/donor). Tissues are (1) heart, (2)
oesophagus, (3) stomach, (4) jejunum, (5) colon, (6) pancreas,
(7) liver, (8) cerebellum, (9) frontal cortex, (10) spinal cord, (11)
trachea, (12) lung parenchyma, (13) kidney, (14) bladder, (15)
ovary, (16) uterus, (17) vas deferens, (18) testis, (19) spleen, (20)
skin. (see Coleman, [26]).
receptor for the hormone [27]. With such a diﬀerence, it is
inconceivable that the 5-HT2b receptor in these two species
serves the same role.
This is not to say that all animal tests are valueless; for
some classes of drug, particular animal tests have proved
highly predictive of clinical eﬃcacy and/or safety. However,
thisispatentlynotageneralrule,andvalidationorotherwise
is only achieved with the beneﬁt of hindsight, providing a
rather insecure basis for assessing novel chemical entities. It
is undoubtedly timely, therefore, to question the continued
useof animal surrogateson the basisof both ethics and logic.
This is a view supported by a number of critical publications,
including that of [28], which showed that the likelihood
of animals predicting human clinical outcome was not
signiﬁcantly better than 50:50. So, if animals’ performance
in this regard is so poor, why do we continue to use them?
There are a number of reasons, some of these relating simply
to the way things have always been done, the insistence of
the regulators for animal data, and of course the diﬃculty in
ﬁnding an alternative.
3. AreNonanimalAlternativesPossible?
The obvious alternative is to concentrate on human, rather
than nonhuman, biology in preclinical testing. But how? The
three approaches available to the drug discovery scientist are
in vivo, in silico, and in vitro.
A number of noninvasive techniques have been devel-
oped to evaluate drug activity in human subjects, such as
CAT, MRI, PET, and SPECT scans, transcranial magnetic
stimulation (TMS), and laser Doppler perfusion imaging
although the value of these for determining potential safety
of new medicines is not clear. However, there is increasing
interest in the use of microdosing (i.e., administration of
doses some 100-fold lower than the lowest intended clinical
dose), and there is a growing body of evidence that it
h a sp r e d i c t i v ev a l u e[ 29–31]. There is little doubt that if
the early encouraging data are replicated, this approach
will be increasingly used in future drug testing. However,
this approach is primarily of value in exploring the likely
pharmacokinetic fate of new drugs and provides limited
information as to eﬃcacy or safety although it can provide
an early indication of the likely generation of potentially
hazardous or indeed eﬃc a c i o u sm e t a b o l i t e s .I ti sr e l e v a n ta t
this stage to mention drug testing in brain-dead individuals,
amodelthathasbeenconductedcontinuously,albeitatalow
level for over 25 years [32]. This approach, which technically
has a lot to commend it, uniquely permitting the generation
of highly relevant data, raises a number of ethical issues,
which are beyond the scope of the present paper, and which
Iw i l ll e a v et oo t h e r st od e b a t e[ 33].
In contrast, in silico testing raises no such ethical issues,
and is becoming increasingly accepted as a part of the
preclinical proﬁling of new drugs. In silico testing, using
computational approaches, is showing promise although
at present, it is generally recommended that a consensus
of indicators from a variety of diﬀerent models be used,
rather than relying on a single model. However, with many
models already commercially available, the reliability of
this approach to predicting drug behaviour in humans will
undoubtedly grow, and as a result of the European REACH
Directive [34], it is now supported by the OpenTox program
[35] .H o w e v e r ,t h i si sa l w a y sl i k e l yt or e m a i nas u p p o r t i v e
element, rather than a primary indicator.
It is clear that such in vivo and in silico approaches are
increasingly accepted as key contributors to today’s drug
development programs, and as such, they will not be dealt
with further in this paper. The area that is really being sorely
neglected is the use of human in vitro techniques. The value
of the in vitro approach is nicely illustrated by TGN1412,
where following its disastrous clinical trial [15], an in vitro
method was rapidly developed that modelled the potentially
fatal cytokine storm experienced by the clinical volunteers
[36, 37]. Had this been developed and used before exposing
human subjects to the drug, the trial would never have taken
place. Surely, the time has come for there to be a rigorous
prospectiveevaluationofhuman-basedapproaches,notonly
in vivo and in silico, but critically also in vitro, as alternatives
to the deeply ﬂawed, animal-based approaches in current use
in the identiﬁcation of potential safety issues for new drugs
in man.
3.1. Human Biology-Based Methods. Despite the establish-
ment in 1959 of Russell and Burch’s principle of the 3Rs
[38], the introduction of nonanimal tests for safety has been
painfully slow, and of human-based tests even slower. It was
notuntilthe1970s,whenAmesetal.introducedhisbacterial
mutagenicitytest[39],thattheﬁrstnonanimaltestwasmade4 ISRN Pharmaceutics
a regulatory requirement. However, since Ames, there have
beenfewothernonanimal teststhathaveachievedregulatory
accreditation and those that have are limited largely to
dermal toxicity and mutagenicity testing [40, 41]. However,
there are a few animal cell/tissue tests [42] that could
theoretically utilise the corresponding human material, but
in the main, in vivo animal tests remain the basis of the bulk
of regulatory required safety testing. Interestingly, a human
cell-based test has now been developed to replace the Ames
Test[43],butithasyettobegrantedregulatoryaccreditation.
Exactly why more eﬀort is not being put towards developing
more human-based test systems is not clear, but it does
appeartobesomethingofaviciouscircle,withbothindustry
and the regulatory authorities waiting for the other to make
the ﬁrst move. But what is certain is that the regulators
will only approve any approach when there is convincing
demonstration of value, so it is clearly down to industry to
take up the challenge.
Much use may be made of human isolated cells and
tissues in supporting pharmaceutical R&D through the
application of relatively straightforward in vitro assays, such
as blood cells, hepatocytes, pancreatic islets, and various
smooth muscle preparations, but one of the prime objec-
tions to adoption of in vitro human tissue models is that
it is impossible to adequately model the complexity of
the whole body in isolated tissues. While this argument
undoubtedly has some validity, it is too easy simply to say
“it cannot be done”, a position that seriously undervalues
human ingenuity when faced with a seemingly intractable
problem. Indeed, with the development of powerful new
technologies, such modelling may be nearer to realisation
than is generally appreciated. The ability of scientists to
model complex pathological processes using a combination
of simple assays is illustrated by the apparently successful
method of predicting nausea and vomiting in man using a
range of approaches including the use of human cells [44].
The answer almost certainly lies not only in considering
drug actions on cell types in isolation, but also through the
integration of a range of technological approaches applied
to human tissues and cells under conditions that better
reﬂect the cell:cell, tissue:tissue, and even organ:organ
interactions that are operational in the human body. Such
an integrated in vitro approach may be regarded as “proxi-
vivo”. There have been considerable advances in the devel-
opment of such constructs. This is particularly important
in considering the eﬀects not only of the drugs themselves,
but also of their metabolic products, and these are likely
to be generated by tissue(s) other than that in which an
adverse eﬀect may originate. Such integrated modelling is
being provided in a range of diﬀerent forms (Figure 3), for
example, using microﬂuidics [45, 46], the so-called quasi-
vivo multicompartmental modular system [47], or wells
within wells [48], all of which allow drugs to be exposed
to key tissues in a fashion approximating that in vivo.S u c h
approaches allow for example the exposure of a drug to
liver cells prior to contact with cells of a target organ(s),
allowing an understanding of the activity not only of the
drug itself, but also of its metabolic products, more closely
mimicking what is likely to occur in vivo. An impressive
example of this approach is the “lung on a chip” developed
by Harvard scientists [49]. If this model proves useful, it
will undoubtedly eventually be succeeded by “gut on a
chip”, “cardiovascular system on a chip” and many others.
Such coculture has also been used to establish a model of
synovial ﬁbroblast-induced cartilage destruction as a model
of rheumatoid arthritis [50].
There are other ways in which pathophysiologically rele-
vantcellinteractionsmaybeincorporatedinaninvitroassay.
One interesting approach involves exposing pathologically
relevant combinations of cell types to various diﬀerent
challenges, and measuring the release of a wide panel of
gene products [51]. This has shown that the inﬂuence of test
drugs on this pattern of released products can be indicative
of the test compound’s biological mechanism of action.
The use of various analyses of correlation and clustering in
comparison to an extensive reference set allows considerable
insight into both therapeutic and pathological aspects of the
biological proﬁle of novel compounds. Similar approaches
have been developed by other companies, but using other
markers of biological activity, for example, gene expression
[52], transcription factors [53]a n dm i c r o R N A s[ 54]. Such
technologiesrepresenthypothesis-freeapproachesmoreakin
to in vivo safety testing than traditional in vitro assays in
which a compound is commonly assayed against a particular
target in a particular tissue or cell type.
While cell culture systems can be rightly criticised
for their generally nonphysiological nature, particularly in
regard to their limited cell number, inadequate perfusion,
and the existence of edge eﬀects, considerable eﬀorts have
gone into improving on this, with the use of tissue slices,
scaﬀolds and other culture support, and also 3D culture
methods [55–57]. The achievement of more physiological 3-
dimensional cultures involving combinations of relevant cell
types will undoubtedly represent a signiﬁcant step towards
more eﬀective in vitro modelling of in vivo systems.
Another important source of human biological material
is the stem cell. As our understanding of stem cells and
the factors determining their diﬀerentiation grows, they will
undoubtedly prove increasingly useful in the generation of
model constructs for the testing of new drugs for both
eﬃcacy and toxicity [58]. Much work is already underway
under the umbrella of the Stem Cells for Safer Medicines
group [59], whose stated aim is “To enable the creation of a
bank of stem cells, open protocols and standardised systems in
stem cell technology that will enable consistent diﬀerentiation
of stem cells into stable homogenous populations of particular
cell types, with physiologically relevant phenotypes suitable for
toxicology testing in high throughput platforms.” Indeed, as
an example, stem cells have already been used to generate
cardiomyocyte-like cells that can be used to model not just
cardiac ion channel function or QT interval prolongation,
but the potential to induce ventricular arrhythmias associ-
ated with torsade de pointes [60].
The value of any in vitro cell/tissue construct is of course
only as great as the methods applied to detect drug activities.
Theanswertobetterassessmentofdrugeﬀects,bothinterms
of potential eﬃcacy and safety probably lies in an association
of appropriate coculture systems along with improved highISRN Pharmaceutics 5
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Figure 3: Some examples of tests involving cell cocultures. Such methods allow simultaneous application of compounds to multiple cell
types, means of studying the inﬂuence (e.g., via secreted factors) of one cell type over the other, and of the eﬀects of metabolites produced by
one cell type on the function of another. (a) IdMOC technology. Typically, cells are seeded in inner wells (marked in green) and incubated
for 24 hours to allow attachment, after which the larger, rectangular (yellow), well is ﬂooded with media containing substrates or test
compounds. The ﬂooding medium permits interconnection of multiple inner wells cell mimicking the integration of multiple organs via the
systemiccirculation.(b)Upperpanelshowsquasivivosystem,lowerpanelaschematicshowinghowchamberscanbeconnectedinserieswith
diﬀerent cell types in each. The ﬁrst chamber A1 is a dual ﬂow chamber with diﬀerent liquids/media on either side of a porous membrane
or scaﬀold on which cells are being cultured. The A1 type of chamber can be adapted to provide an air-liquid interface by substituting one
of the liquid ﬂows by air. (c) Lung on a chip. Upper panel shows the chips, lower panel a schematic illustrating the detail of the design and
the arrangement of bronchial epithelial and airway vascular endothelium either side of a porous membrane. Chips are 2cm—long polymer
devices designed to mimic the function of the human lung. The microﬂuidics system incorporates an alveolar-capillary interface that is
ﬂanked by two side chambers. The alveolar-capillary interface consists of a porous, ﬂexible, 10µm—thick polymer membrane coated with
extracellular matrix (ECM) that separates a channel containing human alveolar epithelial cells and a layer of air from a channel containing
human pulmonary microvascular endothelial cells and a ﬂowing layer of cell culture media. Application of vacuum to the side chambers
deforms the thin walls separating those chambers from the interface, causing the ﬂexible polymer membrane to stretch—thus mimicking
the mechanical eﬀects of breathing.6 ISRN Pharmaceutics
content type methods of detecting biological activity. Such
approaches combined with modern clustering analysis and
pattern recognition software will enable identiﬁcation of
activities undetectable by more conventional in vitro meth-
ods [61–63]. Such approaches are currently incorporated
in the US EPA’s ToxCast programme, which is speciﬁcally
designed to identify better ways of identifying human safety
both for environmental chemicals and more recently for
pharmaceuticals [64].
There is no intention to suggest that at present we are
in a position to simply switch from the current, largely
animal-based system of safety testing to a more human-
focused battery of tests. But on the basis of the considerable
developments made in recent years, the onus now is on the
biopharma industry and academia to apply themselves to
the task of exploiting the ever-increasing range of human
tissue-based technologies to develop more relevant and
predictive methods of establishing the safety and eﬃcacy
of new medicines, and for government and the regulatory
authorities to provide all the necessary encouragement.
It is highly likely that there will prove to be toxicities and
disorders for which isolated cells and tissues do not, and may
never, provide the whole answer, and where some reliance on
experimental animals must remain. In such cases, however,
comparative studies of relevant cells, tissues and associated
pathophysiological processes in man and the chosen animal
species should be undertaken to establish the relevance of
the proposed animal model, before valuable resource is
potentially wasted in the simple hope that the results will
have clinical relevance.
4. Access to HumanBiological Materials
While the attraction of human in vitro studies is in the
wide range of functions that can be studied, it must be
acknowledged that unless we improve radically our access
to viable human tissues, such testing will represent a con-
siderable bottleneck in preclinical drug testing programmes.
At present in the UK we are limited almost exclusively to
acquisition of tissues from surgery and post mortem. While
tissue acquired from these sources is of considerable value, it
is not enough. From these sources, we are limited in terms of
the range of tissue types, the quantity that may be supplied,
the quality and the frequency. These are issues that must be
addressedifhumantissueisevertobecomeakeycomponent
of preclinical eﬃcacy and safety testing. I would suggest that
the answer lies in access to tissues from both heartbeating
and nonheartbeating organ donors. In the UK alone, there
are more than 17 million people currently on the transplant
donor register, and in the year between 1 April 2009 and 31
March 2010, over 3,700 organ transplants were performed
[65]. If each of the donors of those organs had additionally
donated nontransplantable organs/tissues for research, a vast
amount of human-based research would have been possible.
And this is potentially only the tip of the iceberg, as the UK
Department of Health is currently striving to increase the
availabilityoforgansfortransplantthroughtheinstitutionof
NHS Blood and Transplant, and it would be hugely valuable
if all organ retrieval for transplantation could be associated
with additional retrieval of material for research.
But for human tissue research to be adopted as a key
component of the drug testing paradigm, it must become a
“need to have”, and that will only happen if it is demanded
as a regulatory requirement. This will not happen until we
can guarantee access to tissues of the required range, of
appropriate condition, in suﬃcient quantity and with the
necessary frequency. Collaboration between NHS Blood and
Transplant and the pharma industry, together with buy-in
by the general public to facilitate the availability and use
of human tissue for research is essential to realise the full
potential of a human-based approach to drug discovery and
development.
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